Novartis Ag (NVS) Receivables - Other (2016 - 2025)
Novartis Ag (NVS) posted Receivables - Other of $1.1 billion for Q4 2025, up 4.01% sequentially from $1.1 billion in Q4 2024, and up 4.01% YoY from $1.1 billion in Q4 2024.
Novartis Ag (NVS) Receivables - Other (2016 - 2025) Analysis & Trends
Novartis Ag has reported Receivables - Other for 10 years, with the latest figure at $1.1 billion in Q4 2025.
- Quarterly Receivables - Other rose 4.01% year-over-year to $1.1 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 billion (up 4.01% YoY) and the FY2025 annual result came in at $1.1 billion, up 4.01% from the prior year.
- Receivables - Other rose to $1.1 billion in Q4 2025 per NVS's latest filing, from $1.1 billion in the prior quarter.
- Over five years, Receivables - Other peaked at $1.3 billion in Q4 2023 and troughed at $793.0 million in Q4 2021.
- A 5-year average of $1.0 billion and a median of $1.1 billion in 2024 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2021 and 2023: Receivables - Other declined 17.65% in 2021, then surged 30.69% in 2023.
- Over 5 years, Receivables - Other stood at $793.0 million in 2021, then gained by 20.81% to $958.0 million in 2022, then soared by 30.69% to $1.3 billion in 2023, then fell by 12.38% to $1.1 billion in 2024, then climbed by 4.01% to $1.1 billion in 2025.
- According to Business Quant data, Receivables - Other over the past three periods registered $1.1 billion, $1.1 billion, and $1.3 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.37 Bn | 633.61 Bn | 17.26 Bn |
| 2 | AbbVie | 471.07 Bn | 464.50 Bn | 12.70 Bn |
| 3 | Merck | 378.82 Bn | 371.68 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.27 Bn | 295.58 Bn | 11.24 Bn |
| 5 | Astrazeneca | 259.11 Bn | 254.21 Bn | 12.86 Bn |
| 6 | Amgen | 237.62 Bn | 223.63 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 183.34 Bn | 180.16 Bn | 6.22 Bn |
| 8 | Pfizer | 161.05 Bn | 149.36 Bn | 10.94 Bn |
| 9 | Gsk | 106.03 Bn | 101.87 Bn | 8.24 Bn |
| 10 | Sanofi | 55.24 Bn | 47.86 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.14 Bn |
| Dec 31, 2025 | 1.14 Bn |
| Dec 31, 2024 | 1.10 Bn |
| Dec 31, 2024 | 1.10 Bn |
| Dec 31, 2023 | 1.25 Bn |
| Dec 31, 2023 | 1.25 Bn |
| Dec 31, 2022 | 958.00 Mn |
| Dec 31, 2022 | 958.00 Mn |
| Dec 31, 2021 | 793.00 Mn |
| Dec 31, 2021 | 793.00 Mn |
| Dec 31, 2020 | 963.00 Mn |
| Dec 31, 2020 | 963.00 Mn |
| Dec 31, 2019 | 1.17 Bn |
| Dec 31, 2019 | 1.17 Bn |
| Dec 31, 2018 | 1.36 Bn |
| Dec 31, 2018 | 1.36 Bn |
| Dec 31, 2017 | 1.03 Bn |
| Dec 31, 2017 | 1.03 Bn |
| Dec 31, 2016 | 1.03 Bn |
| Dec 31, 2016 | 1.03 Bn |